While many US biotech companies feel trapped within the FDA regulatory framework, high-quality clinical ecosystems exist globally. If domestic regulatory authorities impose unreasonable requirements or spurious timeline delays, startups can conduct clinical trials in other rigorous jurisdictions. Australia, for instance, offers robust hospital infrastructure, precise diagnostic laboratories, and efficient regulatory oversight that can maintain high standards while sustaining trial momentum.

Biotechs are strategically using Australia's speed to their advantage. By starting a Phase 1 trial in Australia in parallel with a US IND application, they can collect early data from healthy volunteers and a small patient cohort. This data can then be used to strengthen the US filing, potentially justifying a higher starting dose or an improved trial design.

US biotechs increasingly use sites like Australia to accelerate development, as Create Medicines did by moving from concept to clinic in under 12 months. What was once viewed with suspicion is now a key strategy to generate data faster and more cheaply, competing with the speed of China's ecosystem.

The global landscape for early-stage clinical trials is shifting, with the U.S. at risk of falling behind. Australia has established itself as a trendsetter and a primary destination for first-in-human studies, while China is accelerating development by leveraging "China speed" and a higher regulatory risk tolerance.

China’s efficiency in early-stage clinical trials is not a threat but a global asset. It allows for faster generation of proof-of-concept data, which helps de-risk programs for all companies before they undertake expensive, global trials for FDA approval.

Through massive government investment in biotech infrastructure, China has become the global hub for early-stage clinical drug development. Both Chinese and Western companies now conduct initial human trials there to move much faster and at a significantly lower cost, giving China a strategic foothold in the pharma value chain.

Moving first-in-human studies to countries like Australia and China is now a core business strategy, not just a cost-saving measure. It allows U.S. biotechs to navigate a more flexible regulatory environment and accelerate development timelines.

China's ability to accelerate biotech development stems from faster patient recruitment for clinical trials. With a large, treatment-naive patient population willing to participate in studies, early-stage oncology trials can be completed in about half the time it takes in the US. This provides a significant strategic advantage for de-risking assets more quickly and cheaply.

Legend's R&D model leverages early-stage, investigator-led trials in China to generate clinical data rapidly. This approach allows the company to make quicker, more informed decisions about which programs to advance into larger, global development, creating a more efficient and data-driven pipeline.